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Why the Omega-3 Piggy Should Not Go to Market
Abstract
The paper in your April issue by Lai et al. entitled "Generation of cloned transgenic pigs rich in omega-3 fatty
acids" (Nat. Biotechnol. 24, 435–436, 2006) perfectly captures the fundamental problem with American
biotech research. That problem is that scientists pursue their research agenda to further scientific knowledge -
all well and good - but when the project succeeds they invent problems for which their research results can be
marketed as a solution. This unreflective move from 'pure science' to commercialization may end up as
biotech's undoing.
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This is where the role of reviewers and editors 
becomes important.
The GEO database has had mechanisms for 
anonymous reviewer access to prepublication 
data since 2003. Over the past several years, 
authors have occasionally requested curator 
comment regarding the level of MIAME 
compliance of their submissions, and we 
have been happy to offer feedback on areas 
that could be improved. GEO staff are 
similarly available to support reviewers and 
editors by providing tailored inspections of 
MIAME compliance of specific submissions 
upon request of the journal, as ArrayExpress 
proposes to do in their correspondence in 
the November issue of Nature Biotechnology6. 
If a reviewer determines that insufficient 
information has been supplied, the GEO 
database is designed such that authors can 
quickly respond by updating their records 
accordingly.
It has been challenging to find the 
optimal balance between submitter effort 
and the appropriate level of metadata detail 
to request, all within a rapidly evolving 
technological and social environment7. 
However, the relative simplicity of the 
GEO database structure, together with 
common-sense curation policies that focus 
on gathering germane MIAME elements, 
have made it possible for us to develop an 
extensive suite of utilities that makes the 
volumes of complex data archived at GEO 
accessible and easy to use by the research 
community at large8. Ultimately, the value 
of a database is reflected in how it is used by 
the community it serves. In the past month, 
GEO received approximately one million 
query hits and over 200,000 file transfer 
downloads amounting to over 2.5 terabytes 
of compressed data. Furthermore, it is clear 
that researchers are applying these data to 
their own studies, as demonstrated by over 
100 recent publications citing data found in 
GEO to support or otherwise complement 
their own studies9. We view this as testament 
that the effort involved in making expression 
data public through GEO is fully justified.
Ron Edgar & Tanya Barrett
National Center for Biotechnology Information, 
National Library of Medicine, National Institutes 
of Health, 45 Center Drive, Bethesda, Maryland 
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Why the omega-3 piggy should not 
go to market
To the editor:
The paper in your April 
issue by Lai et al. entitled 
“Generation of cloned 
transgenic pigs rich in 
omega-3 fatty acids” (Nat. 
Biotechnol. 24, 435–436, 
2006) perfectly captures 
the fundamental problem 
with American biotech 
research. That problem is 
that scientists pursue their 
research agenda to further 
scientific knowledge—all 
well and good—but when 
the project succeeds 
they invent problems for 
which their research results can be marketed 
as a solution. This unreflective move from 
‘pure science’ to commercialization may end 
up as biotech’s undoing.
The omega-3 pig is 
just the latest ‘product’ to 
follow this pattern. Recall 
the case of cloned cattle. 
As science, these projects 
had value in adding to 
our understanding of 
the process of cloning 
and the mechanisms 
of reproduction. But 
the attempt to employ 
this technology for a 
marketable product has 
hit a hurdle. Although 
the safety data on milk 
and meat from cloned 
cattle appear definitive, 
the US Food and Drug Administration still 
continues to drag its feet and has failed to 
lift the moratorium on the release of cloned 
products into the food supply—after three 
years. Why? In short, because no one wants 
to eat them. Of course, it’s a longer story 
than that, but if there were either market 
demand or a pressing need for this product, 
that moratorium would have been lifted long 
ago.
The story of the omega-3 pig has a 
parallel plot. Early transgenic projects in 
pigs demonstrated an important proof of 
concept, but creating omega-3–enhanced 
pigs seems to come from the “because 
we can” school of justification. Even if 
the benefits of dietary omega-3 were 
incontrovertible (which they’re not)1, 
and even if the only sources of omega-3 
were animal based (which they aren’t), 
the rationale for creating these genetically 
modified (GM) pigs is specious at best. Thus, 
in their paper, Lai et al. write, “The only 
way to enrich the tissues of mammals with 
n-3 fatty acids has been dietary provision 
of n-3 fatty acids. Thus, the food industry 
must feed animals with flaxseed, fish meal or 
other marine products. In view of the decline 
in marine fish stocks and the potential 
contamination of fish products with 
mercury and other chemicals, alternative, 
land-based dietary sources of n-3 fatty acids 
are needed.” What happened to flaxseed?
But you might say of the super-pig, “so 
we don’t need them, and few people are 
likely to buy them. Why not let market 
forces decide the fate of this product post-
commercialization?” There are four reasons 
why this pig ought not to go to market.
First, the use of transgenic technology 
for this application represents the worst 
type of ‘research waste’: precious scientific 
resources of time, mental energy and 
money that could be used to tackle serious 
human and environmental threats are being 
devoted to a frivolous cause. The list of 
devastating problems begging for a scientific 
solution include: chronic, genetic and 
infectious diseases, famine, food and water 
safety, global warming, the destruction of 
ecosystems—the list goes on and on. Because 
this project was supported by public money, 
including several US National Institutes of 
Health grants and one from the US National 
Cancer Institute, it took funding away from 
other projects that could have been more 
beneficial.
Second, the one problem we don’t have is 
a shortage of omega-3—even if it turns out 
to be the nutritional wonder that some tout 
it being, which is now in doubt1. Not only is 
it found naturally in readily available foods 
like walnuts, flaxseed and fish, but it can 
be found in supplements and nutritionally 
supplemented foods like Smart Balance 
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peanut butter, oil and margarine. We 
certainly do have a very serious problem of 
obesity and nutrition in the United States 
(and increasingly elsewhere), but neither 
are problems science needs to solve. We 
are obese because we eat too much, and 
we are unhealthy because we choose to eat 
the wrong foods. Offering us GM pork to 
provide us with a plentiful nutrient is an 
obvious attempt to drum up a need that 
justifies the science.
Third, unlike research on peanut butter, 
omega-3 pork requires extensive research 
on animals. At a time when Americans are 
increasingly concerned about the general use 
of animals in scientific research, the animal 
biotech industry needs to confine its work 
to projects necessary for the achievement of 
important health, safety or medical goals. 
There are surely worthy goals to pursue in 
biotech agriculture and medicine, but this 
isn’t one of them. The concern about animal 
welfare issues is exacerbated in this case by 
the widespread unease with conventional 
husbandry practices for this species: pig 
farming is one of the most highly criticized 
areas in the agricultural sector. Let’s adopt 
universal humane farming practices for this 
intelligent species before we make animal 
welfare matters worse for the pig.
Finally, and for many people, most 
worrisome, there is something profoundly 
amiss in our stampede down the biotech path 
for every trivial application AU:OK?. The level 
of the change now possible, the speed at which 
we can make these dramatic alterations and 
the potential consequences for animals, the 
environment and ourselves—for the world as 
we know it—ought to give us great pause. It 
is naive to think that this research, unbridled, 
will have only a trivial impact. This latest work 
already says a great deal about us, and it isn’t 
flattering. One scientist commented about 
the potential of the omega-3 pig: “People can 
continue to eat their junk food. You won’t 
have to change your diet, but you will be 
getting what you need”2. We are altering the 
genome of an animal to enable consumers 
to continue with their self-destructive eating 
habits. What does this say about us if that is 
reason enough to manipulate sentient life?
Given the significant financial and 
scientific resources that will be required 
to bring this pig to market, the absence 
of any real need for it, let alone a pressing 
one, and the stakes involved in our limitless 
pursuit of animal biotech, this is one biotech 
application that we ought to forego.
Autumn Fiester
University of Pennsylvania, Medical Ethics, 3401 
Market St., Suite 320, Philadelphia, Pennsylvania 
19104, USA. 
e-mail: fiester@mail.med.upenn.edu
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To the editor:
An editorial, “BIO ’06 
visible from space?,” in 
your April issue (Nat. 
Biotechnol. 24, 474, 2006) 
highlights how individual 
states have begun to 
take a more active role 
in the development 
of life science policy. 
Collectively, they are 
spending billions of 
dollars on everything 
from infrastructure and 
direct research funding to 
workforce enhancements 
and investment in 
commercial spin-offs. 
Designed to fill perceived 
gaps at the federal level 
and enhance economic 
competitiveness, many 
state policies are having 
the intended effect of 
accelerating the pace 
of scientific discovery 
and commercialization. 
Others, however, are 
having unintended 
consequences and are 
overly ambitious, placing 
undue strain on limited 
resources and venturing 
into territory best 
managed at the national level.
As alluded to in the editorial, a report 
prepared for the Biotechnology Industry 
Organization (BIO; Washington, DC) by 
Battelle Technology Partnership Practice 
and the State Science and Technology 
Institute that was released in April1 indicated 
that US states are spending billions of 
dollars to support bioscience research and 
infrastructure, and even smaller states that 
have not traditionally invested in developing 
their bioscience base are beginning to 
do so. At least 40 states have elaborated 
strategic plans and a spectrum of policy 
initiatives to enhance development of life 
sciences initiatives. Most notable among 
these initiatives are those supporting stem 
cell research; at least six states have directed 
funding to this area, primarily to get 
around federal bans on such research. The 
expectation of such funding is that the state 
will ultimately benefit economically from 
stem cell–based commercial spin-offs. Other 
state initiatives include R&D infrastructure, 
direct support for research, access to seed and 
venture capital, workforce and educational 
development, and creation of specialized 
entities to assist with commercialization and 
technology transfer.
However commendable these activities, they 
are often insufficient for—and in some cases 
detrimental to—the formation of a robust 
life sciences academic-industrial complex 
that both advances healthcare and drives 
economic growth. For a start, most states lack 
the capacity for long-term planning of basic 
research agendas and for execution of complex 
peer review and grants management free of 
political influences. Most politics are local, 
whereas many health and research priorities 
are national and global in scope.
Second, the number and dollar volume 
of state initiatives is certain to result in 
duplication of efforts across states that far 
exceeds what might be considered healthy 
competition. In the case of stem cell initiatives, 
multiple agencies will be providing regional 
funds in multiple states for similar projects, 
and the basis for differentiation between 
efforts, other than size of the funds available, 
is not clear. Other initiatives fall prey to a 
lack of understanding of the relationship 
between federal funding and facilities like 
research laboratories and business incubators. 
Without long-term funding to fuel research 
initiatives, stimulate training of graduate-level 
scientists and engineers, and drive demand 
for space, a majority of such facilities will be 
underutilized. Under what circumstances, 
then, is it rational for states to attempt to affect 
economic progress through investment in the 
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